Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.60 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15748102 | 0.91 | HPGDS (0.48) | HPGDSCYP4F2CYP4A11KMT2AGABRA5 | |
| SCHEMBL26014756 | 0.90 | HPGDS (0.62) | HPGDSP4HTMKMT2ATP53GABRA5 | |
| SCHEMBL26014757 | 0.85 | KDM4E (0.48) | HPGDSCYP4F2CYP4A11KMT2AL3MBTL1 | |
| SCHEMBL24268560 | 0.85 | TP53 (0.46) | HPGDSP4HTMCYP4F2CYP4A11KMT2A | |
| SCHEMBL21553939 | 0.84 | SMN1; SMN2 (0.49) | HPGDSKMT2AL3MBTL1MEN1 | |
| SCHEMBL14082178 | 0.81 | HPGDS (0.61) | HPGDSKMT2ARIPK1MEN1 | |
| SCHEMBL15133134 | 0.78 | HPGDS (0.48) | HPGDSP4HTMKMT2AMEN1 | |
| SCHEMBL13537054 | 0.77 | L3MBTL1 (0.58) | CYP4F2CYP4A11KMT2AL3MBTL1RIPK1 | |
| SCHEMBL25162195 | 0.77 | NPC1 (0.47) | CYP4F2CYP4A11TP53L3MBTL1 | |
| SCHEMBL18079732 | 0.76 | KMT2A (0.49) | HPGDSKMT2ATP53L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| EP-4245744-A2 | CHEMICALLY CLEAVABLE GROUP | Tagworks Pharmaceuticals B.V. (NL) | 2023-09-20 | — | — | EP | disclosed |
| EP-2922574-B1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B V (NL) | 2023-05-17 | — | — | EP | disclosed |
| US-20210162060-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-06-03 | — | — | US | disclosed |
| US-10967069-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-04-06 | — | — | US | disclosed |
| US-10927139-B2 | Chemically cleavable group | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-02-23 | — | — | US | disclosed |
| US-20210002320-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-01-07 | — | — | US | disclosed |
| US-20190336612-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2019-11-07 | — | — | US | disclosed |
| US-10376594-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2019-08-13 | — | — | US | disclosed |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-10-22 | — | — | US | disclosed |
| WO-2014081299-A1 | ACTIVATABLE LIPOSOMES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081300-A1 | CHANNEL PROTEIN ACTIVATABLE LIPOSOMES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081301-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081303-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002320-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | HPGDS 878/4885P4HTM 2435/4885CYP4F2 143/4885 |
| US-10967069-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | HPGDS 2607/4885P4HTM 1758/4885CYP4F2 770/4885 |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | HPGDS 752/4885P4HTM 2478/4885CYP4F2 129/4885 |
| US-20210162060-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | HPGDS 2607/4885P4HTM 1758/4885CYP4F2 770/4885 |
| US-10927139-B2 | Chemically cleavable group | SQLE, CTRL, ENO1 | HPGDS 752/4885P4HTM 2478/4885CYP4F2 129/4885 |
| US-20190336612-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | HPGDS 2607/4885P4HTM 1758/4885CYP4F2 770/4885 |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KIT, JMJD7, TPSB2 | HPGDS 1094/4885P4HTM 1157/4885CYP4F2 248/4885 |
| US-11857636-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | HPGDS 2607/4885P4HTM 1758/4885CYP4F2 770/4885 |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | HPGDS 2607/4885P4HTM 1758/4885CYP4F2 770/4885 |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | HPGDS 2607/4885P4HTM 1758/4885CYP4F2 770/4885 |
| US-10376594-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | HPGDS 2607/4885P4HTM 1758/4885CYP4F2 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.